
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
The largest US non-profit patient safety organization evaluated 7 COVID-19 rapid tests and found serious deficiencies in usability; none were rated "excellent."






